Skip to main content

Table 1 Characteristics of patients treated with FEC100-taxotere and FEC100-taxotere-herceptin

From: ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors

 

FEC100-taxotere

FEC100-taxotere-herceptin

N = 118

%a

N = 46

%a

Tumor type

Ductal carcinoma

106

89.9

44

95.6

Lobular carcinoma

7

5.9

1

2.2

Other

5

4.2

1

2.2

Tumor size

T0-T1

5

4.3

1

2.3

T2

60

51.7

21

48.8

T3

24

20.7

11

25.6

T4

27

23.3

10

23.3

NA

2

1.7

3

6.5

Histoprognostic grade

SBRI

7

6.7

1

2.5

SBRII

54

51.9

19

47.5

SBRIII

43

41.3

20

50

NA

14

11.9

6

13.1

Nodal status

Positive

63

54.3

30

65.2

Negative

53

45.7

16

34.8

NA

2

1.7

0

0

Hormone receptor status

Positiveb

77

66.3

23

50.0

Negativec

39

33.6

23

50.0

NA

2

1.7

0

0.0

HER-2 status

Positived

5

4.7

46

100.0

Negative

102

95.3

0

0.0

NA

11

9.3

0

0.0

Clinical response

CR

11

12.2

7

21.9

PR

62

68.9

23

71.9

SD

15

16.7

2

6.3

PD

2

2.2

0

0.0

NA

28

23.7

14

30.4

pCR

Yes

25

21.2

18

40.0

No

93

78.8

27

60.0

NA

0

0.0

1

2.2

  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not applicable, pCR pathological complete response.
  2. aPercentages of evaluable patients (except for NA: percentage of all patients).
  3. bEstrogen receptor or progesterone receptor positive.
  4. cEstrogen receptor and progesterone receptor negative.
  5. dIHC3+ or IHC2+/FISH+ or CISH+.